Back to search
FDAFDA · Food and drugs·Recall number D-0096-2018

Clozapine Tablets USP, 100 mg, 500 count bottles, Rx only, Manufactured in Israel by: TEVA PHARMACEUTICALS IND, LTD, Jerusalem Israel, Manufactured For: TEVA PHARMACEUTICALS USA, North Wales, PA, NDC 00093-7772-05

Published December 6, 2017 · Recall initiated: November 9, 2017

Summary

FDA records drug Class II recall D-0096-2018, published December 6, 2017 and initiated November 9, 2017. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 3,870 bottles; Lot: Lot # 39C192, exp 06/2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Tablet/Capsule Specifications; potential presence of broken tablets.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Nationwide
Lot
Lot # 39C192, exp 06/2019
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Clozapine Tablets USP, 100 mg, 500 count bottles, Rx only, Manufactured in Israel by: TEVA PHARMACEUTICALS IND, LTD, Jerusalem Israel, Manufactured For: TEVA PHARMACEUTICALS USA, North Wales, PA, NDC 00093-7772-05 recalled?

Yes. FDA published recall D-0096-2018 on December 6, 2017. Reported hazard: Failed Tablet/Capsule Specifications; potential presence of broken tablets.

What should I do if I have this product?

Voluntary: Firm initiated · Letter